Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Alexandre De Nonneville

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

A. De Nonneville1, A. Gonçalves2, J. Boher3, J. Classe4, M. Cohen5, P. Colombo6, F. Reyal7, M. Chauvet8, E. Jouve9, E. Darai10, G. Blache11, C. Coutant12, P. Gimbergues13, C. Mazouni14, R. Rouzier15, R. Villet16, P. Crochet17, A. Azuar18, E. Lambaudie5, G. Houvenaeghel5

Author affiliations

  • 1 Department Of Medical Oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 2 Department Of Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 3 Department Of Clinical research And Investigation, Biostatistics And Methodology Unit, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 4 Department Of Surgical oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 5 Department Of Surgical oncology, Institute Paoli Calmettes, 13009 - Marseille/FR
  • 6 Department Of Surgical oncology, CLCC Val d'Aurelle, Montpellier/FR
  • 7 Department Of Surgical oncology, Institut Curie, Paris/FR
  • 8 Department Of Surgical oncology, Centre Oscar Lambret, Lille/FR
  • 9 Department Of Surgical oncology, Institut Universitaire du Cancer Toulouse Oncopole, Paris/FR
  • 10 Department Of Gynecologic And Breast Cancers, Hôpital Tenon, Paris/FR
  • 11 Department Of Surgical oncology, Centre Leon Berard, Lyon/FR
  • 12 Department Of Surgical oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 13 Department Of Surgical oncology, Centre Jean-Perrin, Clermont-Ferrand/FR
  • 14 Department Of Surgical oncology, Institut Gustave Roussy, Villejuif/FR
  • 15 Surgery, Institut Curie, 75248 cedex5 - Paris/FR
  • 16 Department Of Surgical oncology, Hôpital des Diaconnesses, Paris/FR
  • 17 Department Of Surgical oncology, Hopital de la Conception, Marseille/FR
  • 18 Department Of Surgical oncology, Hôpital de Grasse, Grasse/FR
More

Resources

Abstract 2344

Background

Hormone receptor-positive, HER2-negative, pT1ab N0 breast cancers (BC) are generally estimated as having a low risk of recurrence after locoregional treatment and adjuvant treatment decisions could be challenging. We examined the impact of endocrine therapy (ET) +/- chemotherapy on outcomes in this population.

Methods

A total of 4,788 patients with pT1ab N0 HR+ HER2- BC were identified from a large cohort of 22,475 consecutive patients who underwent primary surgery at 15 French centres between 2000 and 2014. Endpoints were disease-free survival (DFS) and overall survival (OS). Analyses of causal effect using propensity scores were realized using a logistic regression including age, tumour size, histology, grade, and lymphovascular invasion (LVI).

Results

Of 4,779 patients with pT1ab HR+ HER2- BC, 846 patients did not receive any adjuvant treatment and 3,933 received ET, among which 251 received chemotherapy. Age ≥ 70y, ductal histology, high grade and tumour size > 5mm were independently associated with ET prescription. Age ≤ 40y, LVI and high grade, were independently associated with chemotherapy prescription. At a median follow-up of 47.7 months, ET was independently associated with a significant DFS benefit in multivariate analysis (HR: 0.60 [0.41-0.89]; p = 0.011) with 5-year estimate DFS of 94% (CI95 [92-96%]) without ET vs. 96% (CI95 [95-97%]) with ET, while addition of adjuvant chemotherapy was not (HR: 0.90 [0.39-2.09]; p = 0.813). These results were supported by the analyses of causal effect using propensity scores (HR: 0.48 [0.28-0.83]; p = 0.009 for ET, and HR: 1.54 [0.11-21.8]; p = 0.78 for chemotherapy). OS was not significantly impacted by systemic treatments despite a trend for ET in multivariate (HR: 0.60 [0.36-1.00]; p = 0.051) and in propensity score analyses (HR: 0.52 [0.24-1.11]; p = 0.092).

Conclusions

Adjuvant endocrine therapy is associated with a survival benefit in pT1ab N0 HR+ HER2- BC even with a relatively short follow up. Consistent with current consensus guidelines that do not recommend adjuvant chemotherapy in these tumours, we did not find any benefit of adding chemotherapy to ET. These data provide additional clues to the issue of adjuvant systemic treatments in these tumours.

Clinical trial identification

Legal entity responsible for the study

Gilles Houvenaeghel.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings